Efficacy of Fuyang Tongluo therapy combined with conventional western medicine in elderly patients with coronary heart disease and heart failure
10.12007/j.issn.0258-4646.2024.06.08
- VernacularTitle:扶阳通络法联合常规西医疗法治疗冠状动脉粥样硬化性心脏病心力衰竭老年患者的疗效
- Author:
Songbo CHAI
1
;
Yakang DU
;
Shujuan ZHANG
;
Jiangbo WU
;
Xiaofei WANG
Author Information
1. 三门峡市中医院心病科,河南 三门峡 472000
- Keywords:
Fuyang Tongluo therapy;
coronary heart disease;
elderly patient;
heart failure;
inflammatory axis
- From:
Journal of China Medical University
2024;53(6):531-535
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the therapeutic efficacy of the Fuyang Tongluo therapy combined with conventional western medicine in elderly patients with heart failure due to coronary heart disease.Methods In this single-blind randomized controlled trial,96 elderly patients with coronary heart disease and heart failure were randomly divided into three groups,each consisting of 32 individuals.Control group A was treated with conventional western medicine(atorvastatin combined with metoprolol),control group B with Fuyang Tongluo therapy,and the observation group with Fuyang Tongluo therapy and conventional western medicine.The three groups were compared in terms of therapeutic efficacy and traditional Chinese medicine symptom points as well as blood interleukin(IL)-23 and IL-17 levels,left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD),and left ventricular ejection fraction(LVEF)values before and after treatment.Results The total clinical efficacy rate in the observation group was 93.75%,which was significantly higher than those in control groups A(68.75%)and B(65.63%)(P<0.05).After 4 and 8 weeks of treatment,the primary and minor symptom scores,total symptom scores,LVESD,LVEDD,and IL-23 and IL-17 levels in the observation group were significantly lower than those in control groups A and B(P<0.05).Conclusion The combination of the Fuyang Tongluo therapy with conventional western medicine exhibited good therapeutic efficacy in elderly patients with coronary heart disease and heart failure.These effects were achieved by inhibiting excessive expression of the inflammatory axis factors IL-23 and IL-17 and promoting the recovery of cardiac function.
